Delving into the Latest Updates on Carvedilol with Synapse

Overview

Basic Info

SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions.

Drug Type

Small molecule drug

Synonyms

Carvedilol (JP17/USP/INN), Corever, Pluscor

+ [29]

Target

ADRA1 x adrenergic receptor x β1-adrenergic receptor x β2-adrenergic receptor

Action

antagonists

Mechanism

ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesUrogenital Diseases+ [1]

Active Indication

Atrial FibrillationAngina, StableHeart Failure+ [5]

Inactive Indication

Chronic heart failureDrug Resistant EpilepsyHypertrophy, Left Ventricular+ [3]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

InnoPharmax, Inc.Alvogen Korea Co., Ltd.Waylis Therapeutics LLC

+ [2]

Inactive Organization

Chong Kun Dang Pharmaceutical Corp.

GSK Plc

TSH Biopharm Corp., Ltd.

License Organization

Smithkline Beecham

TSH Biopharm Corp., Ltd.

Shandong New Time Pharmaceutical Co. Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

Japan (19 Jan 1993),

Angina PectorisEssential HypertensionHypertension, Renal

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H26N2O4

InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N

CAS Registry72956-09-3

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

Start Date01 Jan 2026

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06964464

/ Not yet recruitingPhase 4IIT

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Rochester

[+1]

NCT07108075

/ RecruitingNot ApplicableIIT

Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis - a Randomised, Double Blind Study.

Clinically significant portal hypertension (CSPH) is defined as HVPG >10 mmHg. Patients with CSPH are at risk of developing esophageal varices and clinical decompensation (variceal bleeding, ascites, jaundice, encephalopathy), which mark the transition from compensated stage to a stage of the disease (decompensated) associated with higher mortality (1). HVPG is calculated by subtracting the free hepatic venous pressure (FHVP), a measure of systemic pressure, from the wedged hepatic venous pressure (WHVP), a measure of hepatic sinusoidal pressure. HVPG is surrogate marker in many clinical applications such as gold standard test to evaluate presence and severity of portal hypertension (PHT) diagnosis, risk stratification, monitoring of the patients on beta blockers (2). Non selective beta-blockers like propranolol and carvedilol are indicated in adults for primary and secondary prophylaxis of variceal hemorrhage. Acute hemodynamic response to intravenous propranolol with HVPG values coming down to <12 mm Hg or reduction to >20% from baseline have been shown to be associated with reduced long term risk of variceal bleed. Metformin has also recently showed to reduce portal pressure in a randomised control study. The mechanism of action of metformin is different from beta blockers (by increasing nitric oxide by upregulating iNOS and eNOS). Hence we are planning the current work to evaluate Acute portal pressure reduction by Metformin and Carvedilol compared to Carvedilol alone in cirrhosis - a randomised, double blind study.

Start Date14 Jun 2025

Sponsor / Collaborator

Institute of Liver & Biliary Sciences

100 Clinical Results associated with Carvedilol

Login to view more data

100 Translational Medicine associated with Carvedilol

Login to view more data

100 Patents (Medical) associated with Carvedilol

Login to view more data

5,791

Literatures (Medical) associated with Carvedilol

01 Oct 2025·LIFE SCIENCES

Tamsulosin regulates antifibrotic effects in thioacetamide-induced liver damage and ameliorates portal hypertension

Article

Author: Quintanar-Stephano, Andrés ; Medina-Pizaño, Mariana Yazmin ; Saucedo-Cárdenas, Odila ; de Jesús Loera-Arias, María ; Llanos-Angulo, Leonel Alejandro Gómez ; de Oca-Luna, Roberto Montes ; Ventura-Juárez, Javier ; Muñoz-Ortega, Martín Humberto

Liver cirrhosis is one of the leading causes of mortality worldwide, with portal hypertension being the initial sign of decompensation. Recent studies in animal models of liver fibrosis have proposed various treatments that reduce stellate cell activity, with adrenergic antagonists having an impact. This study evaluated the effect of tamsulosin as a potential treatment to reduce fibrosis and portal hypertension in a rat model of cirrhosis, without affecting the regenerative capacity of hepatocytes. In vitro, viability, morphological, and molecular techniques analyzed the challenge between the activation of hepatic LX2 stellate cells with noradrenaline and the possible reduction of this activation with tamsulosin and carvedilol treatments. In vivo, male Wistar rats were intoxicated with thioacetamide for 4 weeks to induce liver fibrosis, then treated orally with carvedilol and tamsulosin for 4 weeks. Hepatic function, histological, and molecular evaluation were made. In-situ perfusion was used to evaluate portal pressure. Norepinephrine (NE) induced increasing collagen-1 and α-SMA genes expression, while reducing PPAR-γ. Tamsulosin inhibited NE-induced proliferation, migration, and activation of HSCs, otherwise carvedilol showed partial effects. In vivo, tamsulosin treatment improved liver fibrosis, reduced collagen I levels, and normalized liver function. Additionally, in a thioacetamide-induced cirrhosis rat model, tamsulosin treatment prevented development of portal hypertension or arterial hypotension. Our results demonstrate that NE promotes hepatic stellate cell activation and fibrosis, while tamsulosin and carvedilol effectively reduce these effects in vitro and in vivo, without affecting the regenerative capacity of hepatocytes. In addition, the treatment also alleviates portal hypertension without causing systemic hypotension.

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases

Article

Author: Boudin, Coralie ; Willeman, Théo ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine

Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.

01 Sep 2025·JOURNAL OF HEPATOLOGY

Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis

Letter

Author: Biros, Dimitrios ; Tsiakas, Ilias ; Kalambokis, Georgios N ; Christaki, Maria ; Milionis, Haralampos

26

News (Medical) associated with Carvedilol

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

24 Aug 2025

·www.echemi.com

Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns

Glenmark Pharmaceuticals has announced a voluntary recall in the US, pulling more than 88,000 bottles of Carvedilol (a high blood pressure drug) and 22,656 bottles of Theophylline (used for COPD) from the market. The affected products were manufactured at Glenmark’s Goa and Pithampur plants in India. The US FDA flagged five Carvedilol lots after detecting N-Nitroso Carvedilol Impurity-1 (NNCI) levels above the permissible 4.0 ppm limit, and one Theophylline lot due to failure in dissolution tests. Both issues prompted Class II recalls, suggesting the risk of serious harm is remote but temporary or reversible side effects are possible. Carvedilol is a beta-blocker for treating hypertension, while Theophylline helps manage asthma and COPD by relaxing airway muscles. Glenmark initiated the recalls earlier this month, emphasizing patient safety and regulatory compliance.

21 Aug 2025

·pharma.economictimes.indiatimes.com

Glenmark orders recall of High BP, COPD drug in US

New Delhi: Glenmark pharmaceuticals has ordered a voluntary recall of its high blood pressure generic Carvedilol and COPD drug Theophylline in the US. According to the US FDA latest enforcement report, the Mumbai-based drugmaker is undertaking recall of over 88,000 bottles of Carvedilol tablets and “22,656 bottles” of Theophylline tablets, manufactured at the company’s Goa and Pithampur-based facilities in India. For Carvedilol the company has announced five separate recalls involving 44,328 bottles; 4,800 bottles; 6,432 bottles manufactured at Goa-plant initiated on August 7. While 17,496 bottles; and 14,976 bottles manufactured at Pithampur-based plant, were initiated on August 6 2025. According to the regulator, all five actions have been announced under a common “ CGMP deviation related to the presence of N-Nitroso Carvedilol Impurity-1 (NNCI) above the FDA’s permissible limit of 4.0 ppm. Meanwhile, for Theophylline tablets manufactured at Glenmark's Goa plant, the voluntary measure was initiated on August 8, 2025, due to failure to meet “Dissolution Specifications.” “Failure results were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria,” the report stated. However, all six recalls five for Carvedilol and one for Theophylline are classed as Class II, meaning that the products may cause temporary or medically reversible adverse health consequences and the probability of serious adverse health consequences is remote. Carvedilol is a small molecule indicated for the treatment of high blood pressure. The drug blocks beta receptors resulting in reduction in oxygen supply which allows blood vessels to relax and reduce resistance thereby leads to lower blood pressure. Theophylline is used in the treatment and prevention of chronic obstructive pulmonary disease (COPD) and asthma. The drug blocks phosphodiesterase enzyme and reduce inflammation which allows muscles around the airways in Lungs to relax and helps to widen air passages. By Online Bureau ,

100 Deals associated with Carvedilol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00255	Carvedilol	C07AG02	DB01136

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Atrial Fibrillation	Japan	Daiichi Sankyo Co., Ltd.	24 Aug 2015
Angina, Stable	South Korea	Alvogen Korea Co., Ltd.	06 Nov 2001
Heart Failure	United States	Waylis Therapeutics LLC	14 Sep 1995
Hypertension	United States	Waylis Therapeutics LLC	14 Sep 1995
Ventricular Dysfunction, Left	United States	Waylis Therapeutics LLC	14 Sep 1995
Angina Pectoris	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Essential Hypertension	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Hypertension, Renal	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Drug Resistant Epilepsy	Phase 3	United States	GSK Plc	01 Dec 2008
Left ventricular systolic dysfunction	Phase 3	United States	-	01 Oct 2005
Hypertrophy, Left Ventricular	Phase 3	United States	GSK Plc	01 Jan 2005
Chronic heart failure	Phase 3	United States	GSK Plc	01 Jan 2002
Pulmonary Arterial Hypertension	Phase 2	United States	GSK Plc	01 Jun 2010
Metabolic Syndrome	Phase 1	United Kingdom	GSK Plc	15 Jan 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04023110 (CCT guide, Pubmed \| Breast Cancer Res Treat)	Phase 1	Breast Cancer	68	Carvedilol	ushugzmzbt(szsrhzoldq) = dhdqrofnxe qohrqdwfhk (nbilpulekn )	Positive	02 Apr 2025
				carvedilol (Usual care)	ushugzmzbt(szsrhzoldq) = bszeuiejfw qohrqdwfhk (nbilpulekn )
NCT03069339 (CAVARLY, Pubmed) Manual	Not Applicable	Esophageal and Gastric Varices \| Liver Cirrhosis	330	Combination of carvedilol and VBL	ughxgwwvuj(cebamovvev) = gvvqgcitdk xwvkgmlykm (jscyerhgaa ) View more	Positive	27 Jul 2024
NCT03736265 (Pubmed) Manual	Not Applicable	Compensated cirrhosis Add-on	205	nucleos(t)ide analog	fbslojwqev(wpaqbhajtp) = wgonmklrqc buorbzjjle (oynhwnjghd ) View more	Negative	01 Apr 2024
				Carvedilol 12.5 mg + nucleos(t)ide analog	fbslojwqev(wpaqbhajtp) = dzrlqauzpr buorbzjjle (oynhwnjghd ) View more
NCT02717507 (PREVENT-HF, Literature) Manual	Phase 2	Heart Failure	182	carvedilol	pyzxxksilj(vytdewlpbk) = betriqieen pmezydvnfz (nrnigvfcao, −0.43 - 0.16) View more	Positive	09 Jan 2024
				placebo	pyzxxksilj(vytdewlpbk) = lfnyeqfita pmezydvnfz (nrnigvfcao, −0.77 - −0.13) View more
NCT00642434 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Hyperglycemia \| Hypertension ... View more	22	Metoprolol (Metoprolol)	ohryhhvmuf = feobzwmymd mdrjkpvxjn (dhnqttbely, edydoyzajc - bdsitwjosd) View more	-	26 Dec 2023
				Carvedilol (Carvedilol)	ohryhhvmuf = wecjezyees mdrjkpvxjn (dhnqttbely, ofeihopddx - mzpwuinypy) View more
NCT03736265 (AASLD2023)	Not Applicable	Hepatitis B \| Fibrosis Add-on	238	NUCs	lcbzlhxzua(bbktqgtilg) = txtjaxabee fcplfkwtbw (qxumuslcsm, 0.36 - 1.77)	Positive	10 Nov 2023
				Carvedilol plus NUCs	lcbzlhxzua(bbktqgtilg) = bzezmhhzet fcplfkwtbw (qxumuslcsm, 0.36 - 1.77)
NCT02717507 (PREVENT-HF \| COG ALTE1621, CTgov)	Phase 2	Malignant Solid Neoplasm \| Heart Failure \| Hematologic Neoplasms	196	Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol))	kueadehxhq(lucicahbwu) = fqlfyociht jefbhvacxg (byzzibkxcq, 0.1711) View more	-	29 Sep 2023
				Pharmacogenomic Study (Arm II (Placebo))	kueadehxhq(lucicahbwu) = fdmdiguyqu jefbhvacxg (byzzibkxcq, 0.1917) View more
NCT01155635 (CAPITAL-RCT, Pubmed \| Am J Cardiol)	Phase 4	ST Elevation Myocardial Infarction	794	Carvedilol	sjmxsiseeh(rfofpchkrc) = dsfogtukdf yabqakuvgn (klyynjjatr ) View more	-	01 Jul 2023
				No β-blocker therapy	sjmxsiseeh(rfofpchkrc) = wxssznntge yabqakuvgn (klyynjjatr ) View more
NCT02717507 (COG ALTE1621, ASCO2023)	Phase 2	Neoplasms	196	Carvedilol	wpfjizetqe(ypygcslbdb) = There were no CTCAE grade ≥3 events wdfhvdbzrp (aqcfuwkxvf ) View more	Positive	31 May 2023
NCT02230891 (CTgov)	Phase 2	Diabetes Mellitus \| Heart Failure \| Hypertension	58	Carvedilol (Carvedilol)	sxktdiwtjc(muyxygovyz) = cavdchwfbl poufechffc (iixauotjty, 4.4) View more	-	29 Sep 2022
				Spironolactone (Spironolactone)	sxktdiwtjc(muyxygovyz) = dmgiibbmnz poufechffc (iixauotjty, 3.25) View more